Chapter 116. Immunization Principles and Vaccine Use (Part 9)

Chia sẻ: Thuoc Thuoc | Ngày: | Loại File: PDF | Số trang:12

Thêm vào BST

Báo xấu

93
lượt xem 8
download

Download Vui lòng tải xuống để xem tài liệu đầy đủ

Table 116-3 Valid and Invalid Contraindications to Vaccination Vaccine Valid Contraindicationa Invalid Contraindication All vaccines in general Serious allergic Mild acute illness with reactions (e.g., anaphylaxis) or without fever to a previous vaccine dose or a vaccine component Precaution: Moderate Mild to moderate local or severe concurrent illness reactions; with or without fever moderate low-grade fever after or a previous dose Lack of previous physical examination in a well-appearing person Current antimicrobial therapy (except certain live bacterial vaccines) Convalescent phase of illness Premature birth (except hepatitis B in some circumstances) Recent exposure to infectious diseases History of penicillin allergy, allergies; allergies; other nonvaccine with relatives receiving desensitization treatment DTaPb Severe allergic Temperature fussiness....

Chủ đề:

Bình luận(0) Đăng nhập để gửi bình luận!

Lưu

Nội dung Text: Chapter 116. Immunization Principles and Vaccine Use (Part 9)

Chapter 116. Immunization Principles and Vaccine Use (Part 9) Table 116-3 Valid and Invalid Contraindications to Vaccination Vaccine Valid Invalid Contraindicationa Contraindication All vaccines in Serious allergic Mild acute illness with general reactions (e.g., anaphylaxis) or without fever to a previous vaccine dose or a vaccine component Precaution: Moderate Mild to moderate local
or severe concurrent illness reactions; low-grade or with or without fever moderate fever after a previous dose Lack of previous physical examination in a well-appearing person Current antimicrobial therapy (except certain live bacterial vaccines) Convalescent phase of illness Premature birth (except hepatitis B in some circumstances) Recent exposure to infectious diseases
History of penicillin allergy, other nonvaccine allergies; relatives with allergies; receiving desensitization treatment DTaPb Severe allergic Temperature of reaction to a previous dose
uncontrolled epilepsy, convulsions, developmental progressive encephalopathy: delay) defer DTaP until neurologic status is clarified and stabilized Precaution: Fever of ≥40.5°C at ≤48 h after a previous dose of DTP or DTaP Collapse or shock-like state (i.e., hypotonic hyporesponsive episode ≤48 h after a previous dose of DTP or DTaP) Seizure ≤3 days after a previous dose of DTP or DTaPPersistent, inconsolable crying lasting ≥3 h/≤48 h
after a previous dose of DTP or DTaP Moderate or severe acute illness with or without fever DT, Td Severe allergic reaction after a previous dose or to a vaccine component Precaution: Guillain- Barré syndrome ≤6 weeks after a previous dose of tetanus toxoid–containing vaccine Moderate or severe acute illness with or without fever
IPV Severe allergic reaction to a previous dose or a vaccine component Precautions: Pregnancy; moderate or severe acute illness with or without fever MMR Severe allergic Positive tuberculin reaction to a previous dose skin test; simultaneous TB or a vaccine component skin testing Pregnancy Breast-feeding Known severe Pregnancy of immunodeficiency (e.g., recipient's mother or other hematologic and solid close or household contact; tumors, congenital recipient is childbearing-age immunodeficiency, long- female or immunodeficient term immunosuppressive family member or household
therapy, or severely contact; asymptomatic or symptomatic HIV infection) mildly symptomatic HIV infection; allergy to eggs Precautions: Recent (≤11 months) receipt of antibody-containing blood products (specific interval depends on product); history of thrombocytopenia and thrombocytopenic purpura; moderate or severe acute illness with or without fever Hib Severe allergic reaction to a previous dose or a vaccine component Age
or severe acute illness with or without fever Hepatitis B Severe allergic Pregnancy; reaction to a previous dose autoimmune disease (e.g., or a vaccine component systemic lupus erythematosus or rheumatoid arthritis) Precautions: Infant weighing
Varicella Severe allergic Pregnancy of reaction to a previous dose recipient's mother or another or a vaccine component close or household contact Substantial Immunodeficient suppression of cellular family member or household immunity contact; asymptomatic or mildly symptomatic HIV infection Pregnancy Precaution: Recent (≤11 months) receipt of antibody-containing blood products (specific interval depends on product) Pneumococcal Severe allergic reaction to a previous dose
or a vaccine component Precaution: Moderate or severe acute illness with or without fever Influenza Severe allergic Nonsevere (e.g., reaction to a previous dose contact) allergy to latex or or a vaccine component, thimerosal; concurrent including egg protein administration of warfarin or aminophylline Precaution: Moderate or severe acute illness with or without fever Pneumococcal Severe allergic polysaccharide reaction to a previous dose vaccines or a vaccine component Precaution: Moderate
or severe acute illness with or without fever a Events or conditions listed as precautions should be reviewed carefully. Benefits and risks of administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered. b Whether and when to administer DTaP to children with proven or suspected underlying neurologic disorders should be decided on a case-by-case basis. Note: DTP, diphtheria and tetanus toxoids and whole-cell pertussis vaccine; DTaP, diphtheria and tetanus toxoids and acellular pertussis vaccine; DT, diphtheria and tetanus toxoids; Td, tetanus and reduced-dose diphtheria toxoids, adsorbed; IPV, inactivated polio vaccine; MMR, measles, mumps, and rubella vaccine; Hib, Haemophilus influenzae type b vaccine. Source: General Recommendations on Immunization. MMWR 51(RR02):1, 2002.